Peptide Laws in New York
Regulatory classification: High Scrutiny
Last reviewed: 2026-09-29
Status summary: Research-use-only vendors ship to this state without state-level restriction as of August 2026. No state has enacted a peptide-specific ban on the research-use channel.
Research channel: Restricted
Compounding channel: Restricted
This educational resource separates the research-use channel from prescription and compounding pharmacy requirements in New York. It is not legal or medical advice.
Research-use channel
Research-use-only vendors ship to this state without state-level restriction as of August 2026. No state has enacted a peptide-specific ban on the research-use channel.
Compounding pharmacy channel
Heightened scrutiny on interstate shipments of compounded medications. Out-of-state pharmacies shipping to New York patients face elevated permit verification requirements. Confirm current registration status of any out-of-state pharmacy before use.
Telehealth prescribing
Elevated scrutiny on telehealth-prescribed compounded medications. The New York AG has pursued consumer protection theories against DTC telehealth weight-loss platforms.
Detailed notes
Elevated scrutiny on telehealth-prescribed compounded medications. The New York AG has pursued consumer protection theories against DTC telehealth weight-loss platforms.
Heightened scrutiny on interstate shipments of compounded medications. Out-of-state pharmacies shipping to New York patients face elevated permit verification requirements. Confirm current registration status of any out-of-state pharmacy before use.
Research-use-only vendors ship to this state without state-level restriction as of August 2026. No state has enacted a peptide-specific ban on the research-use channel.
Enforcement actions
New York applies heightened nonresident pharmacy scrutiny to compounded GLP-1s and has moved against imported peptide vendors.
New York has been among the more active states in pursuing consumer protection theories against direct-to-consumer telehealth weight-loss platforms.
Attorney General investigations into DTC telehealth platforms citing deceptive trade practices and unauthorized medical practice theories.
Key regulatory developments
- New York applies heightened nonresident pharmacy scrutiny to compounded GLP-1s and has moved against imported peptide vendors.
- New York has been among the more active states in pursuing consumer protection theories against direct-to-consumer telehealth weight-loss platforms.
- Attorney General investigations into DTC telehealth platforms citing deceptive trade practices and unauthorized medical practice theories.
State regulatory agencies
Pharmacy oversight: New York State Board of Pharmacy
Medical-practice oversight: New York State Board for Medicine
Sources
Verify current requirements directly with the official agencies before relying on this summary. Rules and enforcement priorities can change after publication.
Frequently asked questions
Are research peptides legal in New York?
Research-use-only vendors ship to this state without state-level restriction as of August 2026. No state has enacted a peptide-specific ban on the research-use channel. Research-use labeling does not make a product approved, prescribed, or appropriate for human or animal use.
What rules govern peptide compounding in New York?
Heightened scrutiny on interstate shipments of compounded medications. Out-of-state pharmacies shipping to New York patients face elevated permit verification requirements. Confirm current registration status of any out-of-state pharmacy before use.
Can peptides be prescribed through telehealth in New York?
Elevated scrutiny on telehealth-prescribed compounded medications. The New York AG has pursued consumer protection theories against DTC telehealth weight-loss platforms.
Where can I verify current pharmacy rules in New York?
Consult the New York State Board of Pharmacy and other applicable state agencies. RUO Codes links to the official board source on this page, but agency rules and enforcement priorities can change.